{
  "symbol": "ABBV",
  "year": 2023,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1873,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.113
  },
  "top_positive": [
    {
      "sent": "Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 2023 2022 United States $ 10,852 $ 11,763 (7.7) % (7.7) % $ 30,773 $ 33,521 (8.2) % (8.2) % International 3,075 3,049 0.8 % 1.4 % 9,244 9,412 (1.8) % 1.6 % Net revenues $ 13,927 $ 14,812 (6.0) % (5.8) % $ 40,017 $ 42,933 (6.8) % (6.0) % 2023 Form 10-Q | 29 The following table details AbbVie\u2019s worldwide net revenues: Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 2023 2022 Immunology Humira United States $ 3,020 $ 4,956 (39.1) % (39.1) % $ 9,420 $ 13,613 (30.8) % (30.8) % International 527 603 (12.6) % (12.2) % 1,680 2,045 (17.9) % (14.8) % Total $ 3,547 $ 5,559 (36.2) % (36.2) % $ 11,100 $ 15,658 (29.1) % (28.7) % Skyrizi United States $ 1,875 $ 1,221 53.5 % 53.5 % $ 4,648 $ 3,081 50.9 % 50.9 % International 251 176 42.5 % 40.7 % 721 508 41.8 % 45.5 % Total $ 2,126 $ 1,397 52.1 % 51.9 % $ 5,369 $ 3,589 49.6 % 50.1 % Rinvoq United States $ 801 $ 505 59.0 % 59.0 % $ 1,895 $ 1,228 54.4 % 54.4 % International 309 190 61.8 % 61.2 % 819 524 56.1 % 61.0 % Total $ 1,110 $ 695 59.8 % 59.6 % $ 2,714 $ 1,752 54.9 % 56.4 % Oncology Imbruvica United States $ 678 $ 849 (20.2) % (20.2) % $ 1,982 $ 2,585 (23.4) % (23.4) % Collaboration revenues 230 286 (19.6) % (19.6) % 711 868 (18.0) % (18.0) % Total $ 908 $ 1,135 (20.0) % (20.0) % $ 2,693 $ 3,453 (22.0) % (22.0) % Venclexta United States $ 281 $ 259 8.1 % 8.1 % $ 811 $ 740 9.4 % 9.4 % International 309 256 21.1 % 19.9 % 888 753 18.1 % 21.4 % Total $ 590 $ 515 14.6 % 14.0 % $ 1,699 $ 1,493 13.8 % 15.5 % Epkinly Collaboration revenues $ 14 $ \u2014 n/m n/m $ 14 $ \u2014 n/m n/m Aesthetics Botox Cosmetic United States $ 388 $ 370 5.0 % 5.0 % $ 1,217 $ 1,232 (1.1) % (1.1) % International 232 267 (13.3) % (10.9) % 747 741 0.7 % 6.0 % Total $ 620 $ 637 (2.7) % (1.7) % $ 1,964 $ 1,973 (0.4) % 1.6 % Juvederm Collection United States $ 116 $ 125 (6.4) % (6.4) % $ 363 $ 420 (13.3) % (13.3) % International 205 227 (9.8) % (8.7) % 681 686 (0.8) % 4.5 % Total $ 321 $ 352 (8.6) % (7.9) % $ 1,044 $ 1,106 (5.6) % (2.3) % Other Aesthetics United States $ 255 $ 265 (4.0) % (4.0) % $ 785 $ 837 (6.3) % (6.3) % International 43 47 (8.1) % (7.0) % 130 130 0.5 % 5.4 % Total $ 298 $ 312 (4.6) % (4.4) % $ 915 $ 967 (5.4) % (4.7) % Neuroscience Botox Therapeutic United States $ 626 $ 584 7.2 % 7.2 % $ 1,827 $ 1,641 11.3 % 11.3 % International 122 115 6.5 % 8.6 % 388 350 10.9 % 16.6 % Total $ 748 $ 699 7.1 % 7.4 % $ 2,215 $ 1,991 11.3 % 12.3 % Vraylar United States $ 750 $ 554 35.2 % 35.2 % $ 1,967 $ 1,473 33.6 % 33.6 % International 1 \u2014 >100.0 % >100.0 % 3 \u2014 >100.0 % >100.0 % Total $ 751 $ 554 35.4 % 35.4 % $ 1,970 $ 1,473 33.7 % 33.7 % Duodopa United States $ 25 $ 22 10.6 % 10.6 % $ 74 $ 72 2.8 % 2.8 % International 93 88 6.6 % 2.3 % 279 279 \u2014 % 1.1 % Total $ 118 $ 110 7.4 % 4.0 % $ 353 $ 351 0.6 % 1.5 % Ubrelvy United States $ 230 $ 160 43.7 % 43.7 % $ 574 $ 483 18.8 % 18.8 % International 3 \u2014 >100.0 % >100.0 % 7 \u2014 >100.0 % >100.0 % Total $ 233 $ 160 45.6 % 45.6 % $ 581 $ 483 20.3 % 20.3 % Qulipta United States $ 131 $ 62 >100.0 % >100.0 % $ 292 $ 106 >100.0 % >100.0 % International 1 \u2014 n/m n/m 2 \u2014 n/m n/m Total $ 132 $ 62 >100.0 % >100.0 % $ 294 $ 106 >100.0 % >100.0 % 2023 Form 10-Q | 30 Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 2023 2022 Other Neuroscience United States $ 55 $ 82 (31.9) % (31.9) % $ 195 $ 400 (51.3) % (51.3) % International 6 5 6.2 % 9.6 % 15 14 6.4 % 11.8 % Total $ 61 $ 87 (29.9) % (29.7) % $ 210 $ 414 (49.3) % (49.1) % Eye Care Ozurdex United States $ 34 $ 35 (4.5) % (4.5) % $ 107 $ 104 2.6 % 2.6 % International 86 71 22.3 % 21.7 % 247 219 13.1 % 16.1 % Total $ 120 $ 106 13.2 % 12.8 % $ 354 $ 323 9.7 % 11.7 % Lumigan/Ganfort United States $ 28 $ 59 (53.0) % (53.0) % $ 142 $ 186 (23.6) % (23.6) % International 63 62 2.7 % 1.4 % 198 205 (3.1) % (0.9) % Total $ 91 $ 121 (24.8) % (25.5) % $ 340 $ 391 (12.9) % (11.8) % Alphagan/Combigan United States $ 30 $ 37 (16.0) % (16.0) % $ 90 $ 161 (43.5) % (43.5) % International 40 36 10.1 % 17.3 % 116 111 4.2 % 10.6 % Total $ 70 $ 73 (3.1) % 0.4 % $ 206 $ 272 (24.0) % (21.4) % Restasis United States $ 104 $ 132 (20.7) % (20.7) % $ 265 $ 518 (48.8) % (48.8) % International 13 10 35.0 % 42.1 % 43 38 14.2 % 20.1 % Total $ 117 $ 142 (17.0) % (16.5) % $ 308 $ 556 (44.5) % (44.1) % Other Eye Care United States $ 114 $ 99 16.3 % 16.3 % $ 334 $ 296 13.0 % 13.0 % International 93 82 11.9 % 12.0 % 288 273 5.1 % 8.6 % Total $ 207 $ 181 14.2 % 14.2 % $ 622 $ 569 9.2 % 10.9 % Other Key Products Mavyret United States $ 167 $ 190 (12.3) % (12.3) % $ 531 $ 562 (5.6) % (5.6) % International 203 193 5.2 % 5.8 % 590 599 (1.5) % 1.8 % Total $ 370 $ 383 (3.5) % (3.2) % $ 1,121 $ 1,161 (3.5) % (1.8) % Creon United States $ 305 $ 336 (9.1) % (9.1) % $ 892 $ 941 (5.2) % (5.2) % Linzess/Constella United States $ 279 $ 262 6.8 % 6.8 % $ 799 $ 742 7.7 % 7.7 % International 9 9 (11.1) % (13.0) % 26 24 7.0 % 9.3 % Total $ 288 $ 271 6.2 % 6.1 % $ 825 $ 766 7.7 % 7.8 % All other $ 782 $ 925 (15.5) % (14.1) % $ 2,214 $ 3,145 (29.6) % (28.5) % Total net revenues $ 13,927 $ 14,812 (6.0) % (5.8) % $ 40,017 $ 42,933 (6.8) % (6.0) % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis.",
      "score": 0.996
    },
    {
      "sent": "AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also reducing debt.",
      "score": 0.986
    },
    {
      "sent": "Reents, evaluated the effectiveness of AbbVie's disclosure controls and procedures as of the end of the period covered by this report, and concluded that AbbVie's disclosure controls and procedures were effective to ensure that information AbbVie is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and to ensure that information required to be disclosed by AbbVie in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to AbbVie's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.",
      "score": 0.93
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    }
  ],
  "forward_snippets": [
    "AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also reducing debt.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands.",
    "AbbVie\u2019s pipeline currently includes approximately 90 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands.",
    "AbbVie\u2019s pipeline currently includes approximately 90 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care."
  ]
}